Collateral sensitivity of natural products in drug-resistant cancer cells

Autoren

Thomas Efferth
Mohamed EM Saeed
Onat Kadioglu
Ean-Jeong Seo
Samira Shirooie
Armelle T Mbaveng
Seyed Mohammad Nabavi
Victor Kuete

DOI

10.1016/j.biotechadv.2019.01.009

ISSN

0734-9750

Zeitschrift

Biotechnology Advances

Sprache

en

Artikelnummer

107342

Paginierung

107342 - 107342

Datum der Veröffentlichung

2020

Status

Published

Herausgeber

Elsevier BV

Herausgeber URL

http://dx.doi.org/10.1016/j.biotechadv.2019.01.009

Datum der Datenerfassung

2023

Titel

Collateral sensitivity of natural products in drug-resistant cancer cells

Ausgabe der Zeitschrift

38

Data source: Crossref

Abstract

Cancer chemotherapy is frequently hampered by drug resistance. Concepts to combine anticancer drugs with different modes of action to avoid the development of resistance did not provide the expected success in the past, because tumors can be simultaneously non-responsive to many drugs (e.g. the multidrug resistance phenotype). However, tumors may be specifically hypersensitive to other drugs - a phenomenon also termed collateral sensitivity. This seems to be a general biological mechanism, since it also occurs in drug-resistant Escherichia coli and Saccharomyces cerevisiae. Here, we give a timely and comprehensive overview on hypersensitivity in resistant cancer cells towards natural products and their derivatives. Since the majority of clinically established anticancer drugs are natural products or are in one way or another derived from them, it is worth hypothesizing that natural products may deliver promising lead compounds for the development of collateral sensitive anticancer drugs. Hypersensitivity occurs not only in classical ABC transporter-mediated multidrug resistance, but also in many other resistance phenotypes. Resistant cancers can be hypersensitive to natural compounds from diverse classes and origins (i.e. mitotic spindle poisons, DNA topoisomerase 1 and 2 inhibitors, diverse phytochemicals isolated from medicinal plants, (semi)synthetic derivatives of phytochemicals, antibiotics, marine drugs, recombinant therapeutic proteins and others). Molecular mechanisms of collateral sensitivity include (1) increased ATP hydrolysis and reactive oxygen species production by futile cycling during ABC transporter-mediated drug efflux, (2) inhibition of ATP production, and (3) alterations of drug target proteins (e.g. increased expression of topoisomerases and heat shock proteins, inhibition of Wnt/β-catenin pathway, mutations in β-tubulin). The phenomenon of hypersensitivity needs to be exploited for clinical oncology by the development of (1) novel combination protocols that include collateral sensitive drugs and (2) novel drugs that specifically exhibit high degrees of hypersensitivity in resistant tumors.

Addresses

Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany. Electronic address: efferth@uni-mainz.de.

Autoren

Thomas Efferth
Mohamed EM Saeed
Onat Kadioglu
Ean-Jeong Seo
Samira Shirooie
Armelle T Mbaveng
Seyed Mohammad Nabavi
Victor Kuete

DOI

10.1016/j.biotechadv.2019.01.009

eISSN

1873-1899

Externe Identifier

PubMed Identifier: 30708024

Open access

false

ISSN

0734-9750

Zeitschrift

Biotechnology advances

Schlüsselwörter

Humans
Neoplasms
Antineoplastic Agents
Biological Products
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Drug Collateral Sensitivity

Sprache

eng

Medium

Print-Electronic

Online publication date

2019

Paginierung

107342

Datum der Veröffentlichung

2020

Status

Published

Datum der Datenerfassung

2019

Titel

Collateral sensitivity of natural products in drug-resistant cancer cells.

Sub types

Research Support, Non-U.S. Gov't
Review
Journal Article

Ausgabe der Zeitschrift

38

Data source: Europe PubMed Central

Abstract

Cancer chemotherapy is frequently hampered by drug resistance. Concepts to combine anticancer drugs with different modes of action to avoid the development of resistance did not provide the expected success in the past, because tumors can be simultaneously non-responsive to many drugs (e.g. the multidrug resistance phenotype). However, tumors may be specifically hypersensitive to other drugs - a phenomenon also termed collateral sensitivity. This seems to be a general biological mechanism, since it also occurs in drug-resistant Escherichia coli and Saccharomyces cerevisiae. Here, we give a timely and comprehensive overview on hypersensitivity in resistant cancer cells towards natural products and their derivatives. Since the majority of clinically established anticancer drugs are natural products or are in one way or another derived from them, it is worth hypothesizing that natural products may deliver promising lead compounds for the development of collateral sensitive anticancer drugs. Hypersensitivity occurs not only in classical ABC transporter-mediated multidrug resistance, but also in many other resistance phenotypes. Resistant cancers can be hypersensitive to natural compounds from diverse classes and origins (i.e. mitotic spindle poisons, DNA topoisomerase 1 and 2 inhibitors, diverse phytochemicals isolated from medicinal plants, (semi)synthetic derivatives of phytochemicals, antibiotics, marine drugs, recombinant therapeutic proteins and others). Molecular mechanisms of collateral sensitivity include (1) increased ATP hydrolysis and reactive oxygen species production by futile cycling during ABC transporter-mediated drug efflux, (2) inhibition of ATP production, and (3) alterations of drug target proteins (e.g. increased expression of topoisomerases and heat shock proteins, inhibition of Wnt/β-catenin pathway, mutations in β-tubulin). The phenomenon of hypersensitivity needs to be exploited for clinical oncology by the development of (1) novel combination protocols that include collateral sensitive drugs and (2) novel drugs that specifically exhibit high degrees of hypersensitivity in resistant tumors.

Date of acceptance

2019

Autoren

Thomas Efferth
Mohamed EM Saeed
Onat Kadioglu
Ean-Jeong Seo
Samira Shirooie
Armelle T Mbaveng
Seyed Mohammad Nabavi
Victor Kuete

Autoren-URL

https://www.ncbi.nlm.nih.gov/pubmed/30708024

DOI

10.1016/j.biotechadv.2019.01.009

eISSN

1873-1899

Zeitschrift

Biotechnol Adv

Schlüsselwörter

Antibiotics
Biologicals
Chemotherapy
Collateral sensitivity
Drug resistance
Marine drugs
Neoplasms
Phytochemicals
Phytotherapy
Antineoplastic Agents
Biological Products
Drug Collateral Sensitivity
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Humans
Neoplasms

Sprache

eng

Country

England

Paginierung

107342

PII

S0734-9750(19)30009-6

Datum der Veröffentlichung

2020

Status

Published

Datum, an dem der Datensatz öffentlich gemacht wurde

2020

Titel

Collateral sensitivity of natural products in drug-resistant cancer cells.

Sub types

Journal Article
Research Support, Non-U.S. Gov't
Review

Ausgabe der Zeitschrift

38

Data source: PubMed

Collateral sensitivity of natural products in drug-resistant cancer cells

Tools